Undisclosed mAb Program(s)

About Kalsiom

Kalsiom is an early-stage biotech company pioneering a novel approach to treating autoimmune diseases by targeting calcium signaling in immune cells. Leveraging unique scientific expertise in calcium signaling and antibody development, the company aims to create first-in-class therapies for conditions with high unmet need, such as those involving B-cell dysfunction. Currently in the preclinical discovery phase, Kalsiom is a private, pre-revenue entity building its foundational technology and pipeline. The company's success hinges on validating its novel mechanism and advancing candidates into clinical development.

Therapeutic Areas